Topical pharmaceuticals Safe, effective, affordable & easy to use

Our aim is to provide innovative pharmaceuticals with greater benefits over existing options.

Safe & Effective

Remedor is developing highly safe and effective topical pharmaceuticals for the wound care market. Remedor is a world leader in innovative topical formulations for wound healing of numerous skin condition areas including diabetic foot ulcers, venous ulcers, bed sores, non-healing chronic wounds, surgical wounds, skin injuries, burns, scalding injuries, skin wounds of genetic disorders and rare diseases and for skin care & regeneration.

Products for multiple wound indications to be released in 2022

We are planning to release our innovative pharmaceuticals for wound treatment very soon. Our topical pharmaceuticals are in the process to be approved by various regulatory jurisdictions including the FDA, EMA and others for wound care around the globe. 

A pipeline of products

WoundaGel

We fight diabetic foot ulcers...

Lead product

WoundaGel is indicated for the treatment of foot ulcer in adult patients with diabetes. WoundaGel is an adjunct therapy, and not a substitute for good diabetic wound care, which includes initial debridement, wound cleansing, pressure relief, and control of infection. WoundaGel will be applied daily onto a clean wound with a dressing covering up to wound healing and ulcer closure. WoundaGel is currently in phase IIb clinical trials and is expected to be approved in EU & Switzerland by the EMA in 2022 and by the FDA in USA in 2023.    

For regulatory reasons we are not able to provide further details on WoundaGel on this website, but more information may be available by the company upon request.

RevidraGel

We provide hope for patients with epidermolysis bullosa...

Orphan drug

RevidraGel is indicated for the treatment of chronic wounds that result from the rare epidermolysis bullosa genetic disease. RevidraGel is an orphan topical pharmaceutical that will be used as supportive wound care in patients with epidermolysis bullosa. The topical treatment with RevidraGel will be an adjunct therapy, and not a substitute for good wound care in patients with the disease, which includes initial debridement, wound cleansing, control of infection and wound covering with non-adhesive wound dressings. RevidraGel will be applied onto clean non-ineffective open wounds with the desired non-adhesive dressings upon a dressing change. RevidraGel is currently in a proof-of-concept clinical trial and is expected to be approved in EU & Switzerland by the EMA in 2022 and by the FDA in USA in 2023.

For regulatory reasons we are not able to provide further details on RevidraGel on this website, but more information may be available by the company upon request.

B-Gel

There is an unmet need to improve quality of life of individuals with serious burns...

Potential product

B-Gel is indicated for the treatment of second degree burn wounds in adult individuals with thermal and scalding skin injuries. B-Gel is an adjunct therapy, and not a substitute for good burn wound care, which includes initial debridement, wound cleansing, and control of infection. B-Gel will be applied daily onto a clean burn wound with a dressing covering up to burn wound healing. B-Gel is currently in phase I/II clinical trials and is expected to be approved in EU & Switzerland by the EMA in 2023 and by the FDA in USA in 2024.    

For regulatory reasons we are not able to provide further details on B-Gel on this website, but more information may be available by the company upon request.

Reskinera Cream

Beauty is in our mind...

Cosmetic product

Reskinera is an antiaging cream that is indicated for skin care and regeneration for in individuals who care for their skin health. Reskinera is a substitute for good skin care, to improve skin hydration and reduce the rate of skin pigmentation. Reskinera can be applied daily onto a healthy skin. Reskinera is currently under investigation and is expected to be in clinical trials in EU & Switzerland in 2020 and in USA in 2021.    

For regulatory reasons we are not able to provide further details on Reskinera Cream on this website, but more information may be available by the company upon request.